Providing Disaster Relief

Aiming to Promote the universal health care Alwaleed Philanthropies "Global" supports CDC via AFENET

World Wide

Africa CDC through AFENET: Strengthening Public Health Emergency Operation Centers

Duration

2020 - 2022

Targeting Group

-Africa CDC HQ (Addis Ababa) -Regional Collaborating Centers

Due to the importance of health, we are keen to actively contribute to its promotion at the local and global levels, and since the Africa CDC is not able to accept donations, funding is directed to AFENET, which is supporting the Africa CDC in implementation of its strategy and is working with National Public Health Institutes across the continent and with Regional Collaborating Centers.

  • The primary goal of this investment is to strengthen preparedness and response of the Africa CDC, one of its Regional Collaborating Centers (RCC) and select African Union member states so that they in a better position to detect, prepare for, and respond to public health emergencies, through strengthening/establishment of functional PHEOCs.
  • The need for each country to have a functional PHEOC has been demonstrated now, more than ever, by the ongoing COVID-19 pandemic.

Africa CDC through Amref: Expanding Financial Resilience in Kenya during COVID-19

Duration

2020 - 2022

Targeting Range

Kenya

(Amref) is the largest NGO in Africa and is a key stakeholder in advancing healthcare policy across the continent. Recently, Amref has played a central role in universal health care (UHC) policy, community health strengthening, and the national response to COVID-19 in Kenya, where this grant is focused.

  • Reducing health inequalities following enhanced access to health care services for poor households.
  • Enhancing oversight of health insurance subsidies at the county level.

Achievements until 2020

  • Project implementation has kicked off in 6 out of 9 target cities in Kenya. 4200 of the 6000 targeted community health workers in the 6 cities have been trained on the digital data collection tool. SES data collection has commenced in 2 of the 6 cities.
  • Amref is currently working with the 6 cities to set up secure servers where their data can be stored. They are also working with the State Department of Social Protection to enable a push of the collected data into the Government of Kenya’s single register so that it can be easily accessed and help decision-making.

Mologic: Rapid Diagnostic Development and Manufacturing

Duration

2020 - 2022

Targeting Range

UK, Senegal.

Mologic UK is a UK-based biotechnology company and manufacturer of rapid diagnostic tests. The company has created a responsive platform to accelerate the development and manufacture rapid diagnostics for epidemics, including COVID-19 with support to date from the UK government, Welcome Trust, and Gates Foundation.

  • Develop rapid antigen and antibody tests that can be produced at scale for low cost in LMICs.
  • Build capacity of laboratories in Senegal to be a hub for testing.
  • Rapidly scale up manufacturing capacity for production of tests.

Achievements until 2020

  • In March, Mologic started the validation process for its COVID-19 rapid diagnostic tests. In June, the company received independent validation from the Liverpool School of Tropical Medicine and certification to begin manufacturing.
  • Mologic moved quickly to ramp up its collaboration with Institute Pasteur in Dakar.
  • Mologic continued to strengthen R&D capabilities in the area of lateral flow rapid diagnostic test development in 2020. They have built internal capabilities and external networks to identify high affinity antibodies and innovative detection chemistries to quickly format new lateral flow tests. This specific investment funded the development of a COVID-19 direct antigen test in 2020. The Mologic test will play a key role toward the diagnoses of COVID-19 infection in low-and middle-income countries (LMICs). Mologic has also expanded capabilities in the area of manufacturing scale up required to meet the growing demand for COVID-19 testing on a global scale.

The COVID-19 Therapeutics Accelerator

Duration

2020 - TBD

Targeting Range

Global

The COVID-19 Therapeutics Accelerator (CTA) was launched by the Bill & Melinda Gates Foundation, Wellcome, and the Mastercard Impact Fund in March 2020. The purpose of the CTA is to dramatically speed up the process of identifying potential treatments for COVID-19, fast-track their development, and prepare for the manufacturing of hundreds of millions of doses.

  • The CTA supports research and development (R&D) to identify treatments for mild cases of COVID-19 and to prevent infection before and after exposure to the virus.
  • In addition to supporting the development of therapeutics, the CTA is working closely with partners on licensing, manufacturing, and distribution of treatments.

Achievements until 2020

  • Ongoing trails: 7 trails
  • Completed trials: 3 trails

Combating COVID-19 fund: Diagnostics

Duration

2021 - 2028

Locations

Sub-Saharan Africa, Latin America, and South Asia

Beneficiaries

Produce and deliver COVID-19 test kits to at least in 25 low- and middle-income countries (LMICs)

Global Access Health (GAH) is the parent entity for Global Access Diagnostics and Mologic, which specialize in low-cost manufacturing and affordable cutting-edge medical technology, including high-quality COVID-19 tests in low- and middle-income countries (LMICs). This project will enable GAH and Mologic to address global health priorities—from the launch of COVID-19 tests in LMICs, to the establishment of extreme volume manufacturing in diagnostics for other endemic diseases and future epidemic preparedness.

The goal of Global Access Health’s project is two-fold:

  • To develop and operationalize low-cost, high-quality COVID-19 tests in low- and middle-income countries
  • To prepare for future pandemics by adapting and developing rapid tests for existing endemic diseases

2021 Accomplishments

Global Access Health has delivered 132,000 test kits to over 10 countries in the Global South, with another 180,000 tests planned for donation.

  • Mozambique: 10,000 tests
  • Bangladesh: 82,000 tests
  • Pakistan: 40,000 tests
  • Ethiopia: 40,000 tests, to be shipped
  • Nigeria: 40,000 tests, to be shipped
  • Democratic Republic of Congo: 20,000, to be shipped
  • Kenya: 15,000 tests, to be shipped
  • Zimbabwe: 15,000 tests, to be shipped
  • South Africa: 10,000 tests, to be shipped
  • Malawi: 10,000 tests, to be shipped

Combating COVID-19 fund: Therapeutics

Duration

2021- 2023

Locations

Malawi, Sierra Leone, and Guinea-Bissau and Liberia

Beneficiaries

Repair 20-30 oxygen plants in sub-Saharan Africa, each reaching at least 65-75 patients per day

The COVID-19 Therapeutics Accelerator (CTA) dramatically speeds up the process of identifying potential treatments for COVID-19. Pressure Swing Adsorption (PSA) plants are the primary facilities that generate and deliver oxygen supply to hospitals and clinics in low- and middle-income countries (LMICs).

Build Health International (BHI) aims:

  • To identify and provide treatments for COVID-19 and deliver them in low- and middle-income countries through access to medical oxygen.
  • To improve patient outcomes and save lives while enabling stronger health systems.
  • To increase local technical capacity to improve high-flow oxygen delivery systems.

2021 Accomplishments

In Malawi, Sierra Leone, and Guinea-Bissau

Build Health International (BHI) assessed PSA oxygen plants in each country, in partnership with the World Health Organization (WHO). The team will use data gathered from these assessments to work with local government authorities and partner organizations to develop individual plans for repair and maintenance of the oxygen plants. As part of these plans, a return visit will be scheduled to conduct repairs onsite.

In Liberia

BHI recently completed an assessment of five medical oxygen plants that serve four major hospitals, in partnership with the Liberian Ministry of Health.

Combating COVID-19 fund: Vulnerable Populations

Duration

2021 - 2022

Locations

20-23 African Union member states

Beneficiaries

20-23 African Union member states

The Africa CDC has developed a third wave response support plan to bridge critical gaps where needed most. The deployment of medical SWAT teams will address critical operational needs of African Union member states, reaching up to half of all severely affected countries with capacity building, additional supplies, technical support, public education, and surveillance and sequencing to monitor variants of concern.

Through the SWAT Team Deployment initiative, Africa CDC aims:

  • To enhance Africa CDC’s response support to COVID-19, through SWAT teams to African Union member states
  • To strengthen on-the-ground capacity and coordination to detect COVID-19, ensuring equity in global efforts to protect the most vulnerable populations

2021 Accomplishments

  • Deploying rapid response teams from Africa CDC to 10 priority countries for 3 to 4 week periods to alleviate immediate needs of member states.
  • Recruiting, training, and deploying local rapid response teams for at least three months in up to 10 priority countries.
  • Supportive activities for the rapid response teams, including supervision, communications, translation, and PPE.
  • Recruiting, training, and deploying community health workers for three months in up to 10 priority countries.
  • Expanding or establishing COVID-19 treatment centers across 7-10 countries.
  • Strengthening and expanding patient admission and care capacities of COVID-19 treatment centers across 7-10 countries.